Your session is about to expire
← Back to Search
SPECT-CT Guided Radiation for Oropharyngeal Cancer (SELECT Trial)
SELECT Trial Summary
This trialis testing if using imaging to guide radiation therapy to one side of the neck can reduce risk of cancer returning or spreading.
SELECT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSELECT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SELECT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I know if I'll receive chemotherapy at the same time as another treatment.I have had initial chemotherapy before surgery.My cancer is in an early stage and hasn't spread far.My cancer is only in the tonsil area, with no or one small nearby lymph node affected.My cancer is in one side of my throat and hasn't spread across the middle.I have had head and neck cancer before or have multiple head and neck cancers at the same time.I've had radiation or major surgery on my neck due to cancer.I have another cancer, but it won't affect this trial's treatment.My cancer is either HPV positive or negative.I am using a highly effective method of birth control.My lymphatic mapping injection can be done in various medical settings.I can take care of myself and am up and about more than half of my waking hours.I am willing and able to fill out a quality of life questionnaire in the available language.I am scheduled for radiation therapy on both sides of my neck.I had surgery for cancer in my tonsils or base of tongue with all visible cancer removed.I will start my radiation therapy within 42 days of being chosen for the trial.I do not have severe health issues like recent heart problems or diseases that prevent radiation therapy.
- Group 1: Lympathic Mapping with SPECT-CT guided Radiotherapy
- Group 2: Bilateral Neck Radiotherapy
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA issued authorization for Lympathic Mapping with SPECT-CT guided Radiotherapy?
"There is prior clinical evidence that supports the saftey of Lympathic Mapping with SPECT-CT guided Radiotherapy, thus it was rated a 3 on our scale."
What is the enrollment size of this experiment?
"Affirmative. Clinicaltrials.gov has information that this research is currently recruiting, having been posted on September 29th 2022 and updated as recently as February 3rd 2023. The medical experiment seeks to enrol 510 participants from a single site."
Is enrollment into this experiment currently open to participants?
"Affirmative. As denoted on clinicaltrials.gov, this research was first made public in September 2022 and recently updated in February 2023. The study is enrolling 510 volunteers at a single site."
Share this study with friends
Copy Link
Messenger